ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2015-02-20
Target enrollment:
Participant gender:
Summary
ARQ 197 or placebo in combination with irinotecan and cetuximab in participants with
metastatic colorectal cancer (CRC), in participants with wild-type KRAS alleles who have
failed front-line systemic therapy, to evaluate the safety, tolerability, and efficacy of ARQ
197, define the recommended dose for Phase 2.
After the recommended dose is determined for Phase 2, participants receive study drug or
placebo with irinotecan and cetuximab.